Sawai Receives Approvals for Two Generic Drugs with Five Strengths

Aug. 15. 2019

Osaka, Japan – August 15, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for two generic drugs with five strengths. The two compounds, Aprepitant and Micafungin Sodium are approved for the first time as generics.

The list of approved products:

1. Aprepitant Capsules 80 mg [SAWAI] , 125 mg [SAWAI] and Capsule Set [SAWAI]

Generic name Aprepitant
Indications Digestive symptoms (nausea, vomiting) resulting from the administration of antineoplastic agents (cisplatin, etc.) (including in delayed phase)
Brand products EMEND® Capsules 80 mg, 125 mg and Capsule Set

2. Micafungin Na 50 mg [SAWAI] for Infusion and 75 mg [SAWAI] for Infusion

Generic name Micafungin Sodium
Indications Infections caused by Aspergillus sp. and Candida sp. such as fungemia, respiratory mycosis and gastrointestinal mycosis
Brand products Funguard® 25 mg, 50 mg and 75 mg for Infusion

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.